Condition: Immune Thrombocytopenia · Sponsor: Incyte Corporation
This study will evaluate the safety and efficacy of tafasitamab in adult participants with primary autoimmune blood cell disorders.
This description comes directly from the study's public registry record.
Incyte Corporation Call Center (US) · 1.855.463.3463 · medinfo@incyte.com
Incyte Corporation Call Center (ex-US) · +800 00027423 · eumedinfo@incyte.com
Always discuss trial participation with your own doctor first.
| Palo Verde Cancer Specialists Palo Verde Hematology Oncology, Ltd Glendale | Glendale, Arizona, United States | Recruiting |
| Usc Norris Comprehensive Cancer Center | Los Angeles, California, United States | Recruiting |
| Rocky Mountain Cancer Centers | Lone Tree, Colorado, United States | Recruiting |
| Yale University School of Medicine | New Haven, Connecticut, United States | Not Yet Recruiting |
| Gnp Research | Cooper City, Florida, United States | Recruiting |
| Beth Israel Deaconess Medical Center | Boston, Massachusetts, United States | Recruiting |
| Montefiore Medical Center | The Bronx, New York, United States | Recruiting |
| Inova Schar Cancer Institute | Fairfax, Virginia, United States | Not Yet Recruiting |
| Fred Hutchinson Cancer Center | Seattle, Washington, United States | Not Yet Recruiting |
| Versiti Bloodcenter of Wisconsin Bcw Milwaukee | Milwaukee, Wisconsin, United States | Not Yet Recruiting |
| St Vincent'S Hospital Sydney | Darlinghurst, New South Wales, Australia | Recruiting |
| Townsville University Hospital | Douglas, Queensland, Australia | Recruiting |
+ 28 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07104565